Medical, Inc., an early-stage company focused on developing
endovascular embolization devices for the treatment of neurovascular and
peripheral vascular diseases, today presented new nonclinical data on
one of its investigational devices at the Society
of Interventional Radiology's (SIR) Annual Scientific Meeting.
Metactive currently has two devices under development, and today's
presentation focused on the company's device that addresses the cerebral
aneurysm market. The company's chief executive officer, F. Nicholas
Franano, MD, made an oral presentation entitled "Over-the-wire Device
for Immediate, Complete and Durable Occlusion of Saccular Cerebral
Aneurysms" during the "Arterial Aneurysms and Dissection" session at the
"Endvascular embolization of cerebral aneurysms with coils was a major
advance when it was introduced more than 20 years ago," said Dr.
Franano. "The technology that we are developing at Metactive builds upon
that innovation by providing a next-generation device that has the
potential to provide better patient outcomes, to be faster and easier
for physicians to use, and to improve hospital profitability."
Physicians treat approximately 280,000 aneurysms per year worldwide
using surgical clips, endovascular coils and flow-diverting stents.
Current treatments are complex and costly, and do not consistently
result in complete and permanent occlusion of aneurysms. At SIR today,
Metactive presented findings from a recent pilot nonclinical study in
which the company's cerebral aneurysm embolic device demonstrated
immediate and complete mechanical occlusion of a large, terminal
saccular aneurysm, as well as full endothelialization and sealing of the
aneurysm neck at one month. By comparison, in the same aneurysm model,
treatment using widely used conventional coils did not provide immediate
and complete occlusion. Compared to coiling, the procedure to place
Metactive's device took half as long, and the devices cost one-third as
much. While Metactive has only completed a handful of nonclinical
procedures to date, these excellent early results support further
"If Metactive can demonstrate that this new device can provide better
clinical outcomes with much lower procedure time and complexity, and
large reductions in cost, then I believe it has the potential to provide
real value for patients, physicians, hospitals and payers -- especially
for large aneurysms," said Kieran Murphy, MD, interventional
neuroradiologist and professor of radiology at the University Health
Network Toronto in Ontario, Canada, and director of clinical faculty at
the Techna Research Institute.
About Metactive Medical
Metactive is developing novel endovascular medical devices for the
treatment of neurovascular and peripheral vascular diseases. Metactive's
first products enable precise and immediate occlusion and rapid sealing
of cerebral aneurysms and other target vessel segments using an
over-the-wire microcatheter platform. For more information, please visit www.metactivemedical.com.
[ Back To NFVZone's Homepage ]